52743-73-4

Usage

Uses

Used in Cognitive Enhancement:
Piracetam is utilized as a cognitive enhancer to improve memory, learning, and focus. It is particularly favored by individuals looking to boost their mental performance in various aspects of life, including academic, professional, and personal pursuits.
Used in Neurodegenerative Disorder Treatment:
In the medical field, piracetam is explored as a potential treatment for neurodegenerative disorders such as Alzheimer's disease. Its effects on cognitive function make it a candidate for managing age-related cognitive decline and improving the quality of life for affected individuals.
Used in Research:
Piracetam is also used in scientific research to study the mechanisms of cognitive enhancement and to understand the role of neurotransmitter systems in learning and memory processes. This research contributes to the broader understanding of brain function and the development of novel therapeutic approaches for cognitive impairments.

InChI:InChI=1/C7H11NO3/c1-2-8-4-5(7(10)11)3-6(8)9/h5H,2-4H2,1H3,(H,10,11)

Upstream product

• 97-65-4 2-methylenesuccinic acid 
• 75-04-7 ethylamine 
• 100911-29-3 methyl 1-ethyl-5-oxo-3-pyrrolidinecarboxylate 
• 617-52-7 Dimethyl itakonate 

Relevant academic research and scientific papers

AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS

The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions or disorders.

NOVEL COMPOUNDS

Disclosed are novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

THIAZOLE DERIVATIVE

Provided is a compound having an agonist action on GPR52, which is useful as a prophylactic or therapeutic drug for mental diseases such as schizophrenia and the like, and the like. A compound represented by the formula (I): wherein each symbol is as defi

CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT

Disclosed are novel compounds of the formula (I)or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is formula (I) X is -0-, -C(R14)2- or -N(R)-; Z is -C(R14)2- or -N(R)-; t is 0, 1, 2 or 3; each R and R2 is independently H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl or alkynyl; each R14 is H, alkyl, alkenyl, alkynyl, halo, -CN, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, -OR35, -N(R24)(R25)or -SR35; R41 is alkyl, cycloalkyl, -S02(alkyl), -C(O)-alkyl, -C(O)-cycloalkyl or -alkyl-NH-C(O)CH3; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula (I). Also disclosed are pharmaceutical compositions and methods of treatment comprising compounds of formula I in combination with other agents useful in treating cognitive or neurodegenerative diseases.